Active Biotech AB Interim report January - September 2015
November 06 2015 - 2:32AM
Laquinimod
- The pivotal CONCERTO clinical Phase 3 study in relapsing
remitting MS (RRMS) is proceeding according to plan and results are
expected in 2017
- The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod's
potential for treatment of primary progressive MS (PPMS), and
LEGATO-HD, for the treatment of Huntington's disease, are
proceeding as planned
Tasquinimod
- The final results from Active Biotech's tasquinimod 10TASQ10
Phase 3 trial were presented at the ECC conference and demonstrated
that while tasquinimod treatment resulted in a prolonged
radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months,
the positive effect on rPFS did not translate into an improved
OS
ISI
- Only commercial activities will be conducted from 2016
Financial summary
MSEK |
July
- Sept. |
|
Jan.
- Sept. |
|
Jan. -
Dec. |
|
2015 |
2014 |
|
2015 |
2014 |
|
2014 |
|
|
|
|
|
|
|
|
|
|
Net sales |
5.2 |
2.6 |
|
11.3 |
7.5 |
|
10.4 |
|
|
|
|
|
|
|
|
|
|
Operating loss |
-22.2 |
-55.7 |
|
-149.7 |
-172.8 |
|
-228.5 |
|
|
|
|
|
|
|
|
|
|
Loss for the period |
-23.4 |
-56.6 |
|
-152.7 |
-174.5 |
|
-231.5 |
|
|
|
|
|
|
|
|
|
|
Loss per share, before and after dilution
(SEK) |
-0.26 |
-0.76 |
|
-1.70 |
-2.33 |
|
-3.02 |
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents (at the end of the
period) |
|
|
|
132.4 |
161.0 |
|
328.5 |
|
For further information, please
contact:
Tomas Leanderson, President
and CEO Tel: +46 (0)46 19 20 95 Hans Kolam,
CFO Tel: +46 (0)46 19 20 44 |
Active Biotech AB(Corp.
Reg. No. 556223-9227)Box 724, SE-220 07 Lund, SwedenTel: +46 (0)46
19 20 00Fax: +46 (0)46 19 11 00 |
The report is also available at
www.activebiotech.com.
Active Biotech AB Interim report January - September 2015
http://hugin.info/1002/R/1964749/717166.pdf
HUG#1964749
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024